Bruker makes high-performance scientific instruments used to analyze the structure, composition, and behavior of matter at the molecular, cellular, and nanoscale levels. Bruker operates across four segments. BSI BioSpin (~26% of revenue) sells NMR and EPR spectrometers and preclinical imaging systems, primarily to academic institutions and pharma companies; ultra-high field NMR systems can each represent tens of millions of dollars in revenue. BSI CALID (~35% of revenue) covers mass spectrometry, molecular spectroscopy, and microbiology diagnostics, anchored by the timsTOF mass spectrometry platform and the MALDI Biotyper, the dominant tool for rapid microbial identification in hospitals. BSI NANO (~32% of revenue) sells X-ray analysis instruments, atomic force microscopes, semiconductor metrology tools, and spatial biology platforms (CosMx, GeoMx) acquired through NanoString. BEST (~7% of revenue) manufactures superconducting wire for MRI magnets, fusion research, and high-energy physics. Bruker sells primarily through a direct global sales force. Instrument sales are the core revenue driver but are lumpy; aftermarket revenue — services, consumables, and software — represented 38% of BSI revenues in FY25 and is more recurring. In diagnostics, Bruker uses a reagent rental model where instruments are placed with customers and revenue is generated through consumable pull-through over 5-7 years. Bruker manufactures predominantly in Europe but reports in USD, creating meaningful FX exposure. Bruker's growth strategy focuses on proteomics, spatial biology, infectious disease diagnostics, and lab automation, supported by several large acquisitions completed in 2024.